Moroxite
Developing Breakthrough therapies In
Targeted Drug Delivery
We are Moroxite
A medtech company, developing portfolio of breakthrough therapies to revolutionize the existing treatment paradigms. We provide innovative nano and micro technology based platform for targeted drug delivery.
We are committed to make societal contribution by discovering and developing innovative solutions for major diseases with unmet medical needs.
Our Mission
Our Expertise
We have developed a platform for prolonged release of apatite binding drugs, using a carrier containing nano and micro particles. The active drugs can be released over an extended period ranging from days to years.
Focus Areas
Recent Updates
Purchase agreement addendum
Moroxite Holding Pte. Ltd (“MHPL”), and Moroxite AB (“MA”) have agreed in an addendum signed by both parties and confirmed by board decision to transfer of 30% shareholding interest in Moroxite T back to MA. The present royalty/license part in the agreement was removed by the addendum. MHPL keeps its commitment to invest up to SEK 43.2 million in Moroxite T, upon fulfilment of agreed milestones.
Full information could be found on https://investor.rexih.com/news.html/id/2450554
Moroxite T AB, a spin off from Moroxite AB, has been acquired by a subsidiary of REX International Holding (REX), a Singapore based stock listed company. The acquisition is pending approval from REX’s shareholders.
Moroxite T focuses on hindering solid tumour progression and prevent metastasis. Its protected unique carrier platform for targeted cancer therapy uses a combination of nano and micro apatite particles for local delivery. REX and Moroxite T have joined forces to develop a novel closed vacuum mixing system that allows environmentally safe delivery of cytostatic drugs.
Moroxite AB spins-off its Bone Infection business into a new company- Moroxite I AB
In March 2022, the Board of Moroxite AB decided to spin-off the bone infection area into an independent company Moroxite I AB.
Moroxite AB spins-off its Fracture Fixation business into a new company- Moroxite F AB
Background
With extensive preclinical research at Lund University Moroxite AB was founded in 2020 based on nano and micro apatite technology platforms for targeted drug delivery with initial focus on tumour, bone infection and fragility fracture fixation. The intellectual property is protected by several applications in Europe and US.
Moroxite F AB
The fragility fracture fixation concept has been tested and proven in-vitro, in vivo and in osteoporotic human bone explants and is currently undergoing a feasibility study. The compelling research data obtained over the years and the ongoing research has created a strong basis for a focused path for enhancing fracture fixation in osteoporotic bone.
In December 2021, the Board of Moroxite AB decided to spin-off the fracture fixation area into an independent company Moroxite F AB.
Private placement
Moroxite F AB has raised capital 10 MSEK in a private placement on February 11, 2022 from two investors, Fåhraeus Startup & Growth and ALMI invest with 6 MSEK and 4 MSEK respectively.
The board believes that the spinoff will create value for the shareholders with a strategic and operational focus to accelerate company growth.